Lantheus Inc. (LNTH)
92.63
-2.02 (-2.13%)
At close: Jan 14, 2025, 3:59 PM
92.62
-0.01%
After-hours Jan 14, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 80.14 |
| Market Cap | 6.44B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 5.94 |
| PE Ratio (ttm) | 15.59 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 99.9 |
| Volume | 495,950 |
| Avg. Volume (20D) | 1,070,649 |
| Open | 94.58 |
| Previous Close | 94.65 |
| Day's Range | 92.00 - 95.44 |
| 52-Week Range | 50.20 - 126.89 |
| Beta | undefined |
About LNTH
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brai...
Sector Healthcare
IPO Date Jun 25, 2015
Employees 834
Stock Exchange NASDAQ
Ticker Symbol LNTH
Website https://www.lantheus.com
Analyst Forecast
According to 7 analyst ratings, the average rating for LNTH stock is "Buy." The 12-month stock price forecast is $137, which is an increase of 47.90% from the latest price.
Buy 85.71%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Lantheus Inc. is scheduled to release its earnings on Feb 20, 2025,
before market opens.
Analysts project revenue of $385.48M, reflecting a 8.89% YoY growth and earnings per share of 1.64, making a -6.29% decrease YoY.
Analysts project revenue of $385.48M, reflecting a 8.89% YoY growth and earnings per share of 1.64, making a -6.29% decrease YoY.
1 day ago ·
Source
-1.28%
Lantheus Holdings shares are trading lower after t...
Unlock content with
Pro Subscription
1 month ago ·
Source
+8.84%
Lantheus Holdings shares are trading higher after the company announced its board authorized a $250 million share repurchase program.
